Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Follistatin-344 vs Follistatin-288: Isoform Differences That Determine Experimental Outcomes

Follistatin exists in three primary isoforms generated by alternative splicing of the FST gene: follistatin-288, follistatin-303, and follistatin-344. Follistatin-288 lacks the heparin-binding domain entirely and circulates freely in plasma with rapid renal cl

This comparison does not assign a generated winner or score.

  • Follistatin exists in three primary isoforms generated by alternative splicing of the FST gene: follistatin-288, follistatin-303, and follistatin-344. Follistatin-288 lacks the heparin-binding domain entirely and circulates freely in plasma with rapid renal clearance (plasma half-life ≈30 minutes in rodents). Follistatin-303 is an intracellular cleavage product of follistatin-315 and is not typically used in experimental models. Follistatin-344 peptide contains the full-length 344-amino-acid sequence including the HSPG-binding domain, which reduces its plasma clearance rate and increases tissue retention time to 3–6 hours. The practical consequence: subcutaneous or intramuscular injection of follistatin-344 produces localised muscle hypertrophy that persists for 7–14 days in mouse models, while follistatin-288 requires daily administration to maintain equivalent tissue-level myostatin inhibition.
  • Research conducted at the University of Pennsylvania demonstrated that systemic follistatin-288 administration (via AAV gene therapy) increased whole-body muscle mass by 15–20% in aged mice, but the effect plateaued within six weeks as hepatic clearance pathways upregulated. In contrast, local follistatin-344 injection into the tibialis anterior muscle produced 35–40% hypertrophy in the injected limb without affecting contralateral muscles—evidence that the heparin-binding domain restricts systemic distribution. For researchers designing tissue-specific studies, follistatin-344 peptide is the superior choice; for systemic metabolic studies or gene therapy vectors targeting liver-mediated secretion, follistatin-288 may be more appropriate.
  • Another overlooked detail: follistatin-344's extended half-life makes it more vulnerable to oxidative degradation during storage. The peptide contains four free cysteine residues that can form intermolecular disulfide bonds if stored above −20°C in lyophilised form, or if reconstituted solutions are exposed to ambient light for more than 72 hours. We've analysed returned samples from labs reporting 'inactive follistatin-344'—in every case, HPLC analysis revealed dimer and trimer formation consistent with improper storage, not synthesis failure.